PremiumThe FlyVigil Neuroscience downgraded to Neutral from Buy at Guggenheim Vigil Neuroscience downgraded to Market Perform from Outperform at William Blair Vigil Neuroscience downgraded to Market Perform from Outperform at Citizens JMP PremiumThe FlyVigil Neuroscience sees cash runway into 2026 Vigil presents data on oral small molecule program including VG-3927 Vigil Neuroscience Reports 2024 Results and Clinical Progress PremiumCompany AnnouncementsVigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share Dilution Promising Clinical Progress and Strategic Advancements Justify Buy Rating for Vigil Neuroscience Promising Clinical Progress and Strong Financial Position Support Buy Rating for Vigil Neuroscience 
